In PCOS and obesity, more weight loss meant more ovulation — with no upper limit found
A post hoc analysis of the BAMBINI trial asked whether losing too much weight could backfire on fertility in PCOS. It did not: every degree of weight loss was linked to a better chance of ovulating.
Women with polycystic ovary syndrome and obesity are routinely told that losing weight will help their periods and fertility, and modest loss of 5–10% of body weight is known to improve reproductive function. A less settled question is whether there is a point at which more weight loss stops helping, or even harms the chance of ovulating. A 2026 analysis of the BAMBINI trial looked for that ceiling and did not find one: across the range studied, every degree of weight loss was associated with a higher likelihood of ovulatory recovery [s1].
What the study did
BAMBINI was a multicentre, open-label randomised controlled trial run in the UK between February 2020 and April 2023 [s1]. Eighty women with PCOS, a body-mass index of 35 kg/m² or higher, and oligomenorrhoea or amenorrhoea were randomly assigned, one to one, to standard medical care or to vertical sleeve gastrectomy — a form of bariatric surgery [s1]. This report is a secondary, post hoc analysis of 75 of those women followed for 52 weeks, examining how the amount of total weight loss related to the return of ovulation [s1].
The outcome was defined strictly. "Ovulatory recovery" meant two consecutive, biochemically confirmed ovulatory events — a serum progesterone of 16.0 nmol/L or higher — occurring three to five weeks apart within the 52-week follow-up [s1]. The authors then used logistic regression to relate weight loss and reproductive hormones to that outcome [s1].
What it found
By 52 weeks, 50.8% of the women (38 of 75) had achieved ovulatory recovery [s1]. The split by weight change was stark: ovulation returned in 19% of participants who did not lose weight, against more than half of those who did [s1]. Modelled continuously, each 1% reduction in body weight was associated with a 5.6% increase in the odds of ovulatory recovery (OR 0.944, 95% CI, 0.900 to 0.990) [s1]. Importantly, the analysis found no upper threshold of weight loss beyond which the chance of ovulating fell — the central question it set out to answer [s1].
Two hormonal markers pointed the other way. A higher baseline anti-Müllerian hormone (OR 0.963, 95% CI, 0.938 to 0.988; P = 0.004) and a higher total testosterone (OR 0.324, 95% CI, 0.142 to 0.742; P = 0.008) were each associated with lower odds of ovulatory recovery [s1]. Greater weight loss after surgery was accompanied by rising sex hormone-binding globulin and a falling free androgen index — the biochemical fingerprint of easing the androgen excess that drives PCOS [s1].
Why it matters, and why to be careful
The practical reassurance is real: for women with PCOS and obesity, the data give no reason to hold back from substantial weight loss out of fear it will undermine fertility, at least within the range these women achieved [s1]. The hormonal findings also help explain who responds — women with more severe androgen excess or very high ovarian reserve markers may need more than weight loss alone.
But the framing has to be honest, because the authors are. This was an exploratory, post hoc analysis that was not prespecified, and the trial was not powered to detect harm at higher degrees of weight loss [s1]. That means the reassuring "no upper limit" conclusion is a hypothesis supported by these data, not a settled finding — the study simply was not built to prove that very large losses are safe for ovulation. Health Newspapers has reported on other weight-based approaches in PCOS, including time-restricted eating and tirzepatide in real-world use; each addresses the same underlying target from a different angle.
How much to trust it
The parent trial was randomised, the ovulation outcome was defined biochemically rather than by self-report, and the funding is independent and public — the work was supported by the UK Medical Research Council, the National Institute for Health and Care Research, the Biotechnology and Biological Sciences Research Council and the NHS, not by a commercial sponsor [s1]. The weaknesses are the small sample, the single-country setting, and above all the exploratory, unplanned nature of this particular analysis [s1].
What it means for a reader
If you have PCOS and are carrying excess weight, this adds evidence that weight loss — however achieved — tends to restore ovulation, and gives no signal that losing "too much" is counterproductive for fertility. It is not a reason to pursue bariatric surgery specifically, which carries its own risks and indications. Decisions about how to lose weight belong with your own clinicians. This article is informational and is not medical advice.
What to watch
Whether a larger, prospectively designed study confirms that the benefit holds at the highest degrees of weight loss, and whether baseline AMH and testosterone could help identify in advance the women for whom weight loss alone will not be enough [s1].
Sources
Sources
ICSI is used well beyond male infertility. A review finds no live-birth benefit
Injecting one sperm into each egg was meant for severe male-factor cases, yet clinics now use it widely. Pooling six randomised trials found no live-birth advantage over standard IVF when sperm is not the problem.
Do IVF add-ons work? Two large trials and a regulator urge caution
Popular extras like embryo genetic testing and endometrial scratching did not raise live-birth rates in their biggest randomised trials, and the UK regulator warns most patients need none of them.
What actually manages PCOS, according to the international guideline
The 2023 global guideline puts lifestyle first for everyone, letrozole first for fertility, and the pill for cycles and excess hair — while rating much of its own evidence low to moderate quality.
Testosterone gel before IVF did not lift pregnancy rates in women with low ovarian reserve
A European trial stopped early for futility: clinical pregnancy occurred in 15.7% of women given transdermal testosterone before IVF and 14.9% given placebo. The trial was funded by Ferring.